Home » Stocks » HARP

Harpoon Therapeutics, Inc. (HARP)

Stock Price: $23.70 USD -0.47 (-1.92%)
Updated Jan 20, 2021 2:24 PM EST - Market open
Market Cap 778.52M
Revenue (ttm) 12.19M
Net Income (ttm) -52.82M
Shares Out 25.08M
EPS (ttm) -2.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $23.70
Previous Close $24.16
Change ($) -0.47
Change (%) -1.92%
Day's Open 24.11
Day's Range 23.60 - 24.91
Day's Volume 102,341
52-Week Range 10.74 - 24.91

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 6 days ago

Harpoon (HARP) gets Orphan Drug designation by the FDA for HPN217 for the treatment of multiple myeloma.

GlobeNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, to...

GlobeNewsWire - 1 week ago

Underwriters Fully Exercise Option to Purchase Additional Shares Underwriters Fully Exercise Option to Purchase Additional Shares

Zacks Investment Research - 1 week ago

Harpoon (HARP) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares of ...

GlobeNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, an...

GlobeNewsWire - 2 weeks ago

HPN328, Harpoon's fourth TriTAC® T cell engager, enters clinical development HPN328, Harpoon's fourth TriTAC® T cell engager, enters clinical development

Seeking Alpha - 2 weeks ago

Harpoon Therapeutics presents an opportunity in the cancer treatment space, and at the current levels, the stock is a good buy. HPN424, HARP's most advanced product, targets prostate cancer, w...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, to...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, to...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today present...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, to...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, announced tod...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, to...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, to...

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, ...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, ...

GlobeNewsWire - 6 months ago

Joanne Viney, Ph.D., brings expertise as an immunologist and veteran biotech executive to the board

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, ...

GlobeNewsWire - 8 months ago

Initiation of the clinical trial triggers $50 million milestone payment from AbbVie Initiation of the clinical trial triggers $50 million milestone payment from AbbVie

GlobeNewsWire - 9 months ago

SOUTH SAN FRANCISCO, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...

The Motley Fool - 9 months ago

The American Society of Clinical Oncology's annual meeting -- one of the most important healthcare industry gatherings of the year -- will happen without face-to-face contact.

Other stocks mentioned: TRIL
Seeking Alpha - 10 months ago

Harpoon Therapeutics, Inc. (HARP) CEO Gerald McMahon on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Harpoon Therapeutics, Inc. (HARP).

GlobeNewsWire - 1 year ago

Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year

Other stocks mentioned: ABBV
GlobeNewsWire - 1 year ago

HPN328, a TriTAC®, Exhibits the Potency, Tolerability, and Pharmacokinetics to Support Initiation of Clinical Development in 2020

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, ...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, ...

The Motley Fool - 1 year ago

Tag along on two of them -- but watch out for this biotech upstart, on which Wall Street might be a little early.

Other stocks mentioned: CRM, RGLD

About HARP

Harpoon Therapeutics, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536, which is in Phase I/IIa clinical trial for the treatment of ovarian cancer and other MSLN-expressing tumors; H... [Read more...]

Industry
Biotechnology
IPO Date
Feb 8, 2019
CEO
Gerald McMahon
Employees
77
Stock Exchange
NASDAQ
Ticker Symbol
HARP
Full Company Profile

Financial Performance

In 2019, HARP's revenue was $5.78 million, an increase of 21.62% compared to the previous year's $4.75 million. Losses were -$55.57 million, 103.1% more than in 2018.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for HARP stock is "Strong Buy." The 12-month stock price forecast is 31.89, which is an increase of 34.59% from the latest price.

Price Target
$31.89
(34.59% upside)
Analyst Consensus: Strong Buy